Clinical Trial Update: Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical evaluation of 0.1% olopatadine hydrochloride ophthalmic solution in pediatric patients for allergic conjunctivitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Patanol (olopatadine hydrochloride) ophthalmic solution 0.1% (olopatadine hydrochloride)

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED